Avalo Therapeutics (AVTX) Times Interest Earned (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Times Interest Earned came in at -$0.88 in Q1 2026, up 99.64% YoY from -$0.44 in Q1 2025, and up 99.96% on a QoQ basis from -$2193.6 in Q4 2025.
Avalo Therapeutics (AVTX) Times Interest Earned (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Times Interest Earned data on file, last reported at -$0.88 in Q1 2026.
- Quarterly Times Interest Earned rose 99.64% year-over-year to -$0.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.33 (up 98.46% YoY) and the FY2025 annual result came in at -$1.83, down 75.15% from the prior year.
- Times Interest Earned improved to -$0.88 in Q1 2026, from -$2193.6 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $6.84 in Q3 2022 to a low of -$2193.6 in Q4 2025.
- A 5-year average of -$245.04 and a median of -$13.12 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 248.12% — and 2024, when it slumped 18358.37%.
- Tracing AVTX's Times Interest Earned over 5 years: stood at -$13.12 in 2022, then jumped by 134.36% to $4.51 in 2023, then plunged by 5021.95% to -$221.85 in 2024, then tumbled by 888.76% to -$2193.6 in 2025, then jumped by 99.96% to -$0.88 in 2026.
- The last three Times Interest Earned figures came in at -$0.88 (Q1 2026), -$2193.6 (Q4 2025), and -$325.39 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -0.86 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.86 |
| Mar 31, 2026 | -0.88 |
| Dec 31, 2025 | -2,193.56 |
| Sep 30, 2025 | -325.39 |
| Jun 30, 2025 | -165.09 |
| Mar 31, 2025 | -244.48 |
| Dec 31, 2024 | -221.85 |
| Sep 30, 2024 | -229.66 |
| Jun 30, 2024 | -165.09 |
| Mar 31, 2024 | -595.76 |
| Dec 31, 2023 | 4.51 |
| Sep 30, 2023 | -1.53 |
| Jun 30, 2023 | -6.33 |
| Mar 31, 2023 | -3.23 |
| Dec 31, 2022 | -13.12 |
| Sep 30, 2022 | 6.84 |
| Jun 30, 2022 | -3.80 |
| Mar 31, 2022 | -7.27 |
| Dec 31, 2021 | -22.77 |
| Sep 30, 2021 | -4.62 |